Andrew Combs insider trades
Open-market stock purchases and sales by Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics Inc, from SEC Form 4 filings since Sep 29, 2020.
Track record: 40% of 5 scored buys are up 5% or more since purchase, averaging +50%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Feb 4, 2026 | PRLD Prelude Therapeutics Inc | Bought (not open market) | — |
Companies traded
- PRLD Prelude Therapeutics Inc: 6 buys, last Feb 4, 2026